An examination of X-ray and MRI scans of 518 patients before and after treatment with Levicept Ltd.’s Levi-04 has shown that, in addition to providing significant analgesia, the selective neurotrophin-3 inhibitor may have a disease-modifying effect in osteoarthritis of the knee.
Biomarin Pharmaceutical Inc. plans to divest its pioneering gene therapy for hemophilia, Roctavian (valoctocogene roxaparvovec), and remove what had been considered a potential blockbuster from the portfolio in order to grow the company.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: GSK, Johnson & Johnson, Partner, Ribocure, Suzhou Ribo, Sydnexi.
Biopharma happenings, including deals and partnerships, and other news in brief: Biossil, Chugai, Elevara, Maruho, Medivir, Mitocarex, Nanobiotix, Nielsen, Renalys, Scisparc, Secarna, Scenic, Teijin.
RSS
